Sign in Subscribe

Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam

Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.

Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam
Credit: Alnylam
Already have an account? Sign in.